BioArctic is developing disease modifying treatment for Alzheimer’s disease. One major challenge is the limitations of biomarkers reflecting disease pathology, stage and severity. Thus, there is a need for biomarkers to evaluate the disease modifying efficacy of drugs in clinical trials.
The grant from Vinnova will be used for a collaborative research project within Uppsala Berzelii Technology Centre for Neurodiagnostics; between the Molecular Geriatrics group at the Uppsala University and BioArctic. The research project will further investigate the company’s strategy utilizing bispecific antibodies to increase brain uptake of antibodies via reception mediated transcytosis across the blood-brain barrier (BBB). Previous results have shown an up to 100-fold increased antibody concentration in the brain. In the first study, the bispecific antibody was used as a positron emission tomography (PET) biomarker to image amyloid-beta pathology, the characteristic hallmark of the Alzheimer’s disease brain (Sehlin et al. 2016). To our knowledge, this is the first successful central nervous system PET radioligand based on an antibody.
The even wider potential for the BBB technology is in immunotherapy for neurodegenerative diseases or brain tumors, where efficacy of the therapeutic antibody is believed to be restricted due to low penetration into the brain.
“We are very grateful for the grant for this important research project. We will develop this PET tracer further to be used as biomarker in drug development and potentially future diagnostic tool in Alzheimer patients, says Gunilla Osswald, CEO BioArctic AB.
For more information, please contact:
Gunilla Osswald, CEO, BioArctic AB
Lars Lannfelt, Senior Vice President University Collaborations, Founder, BioArctic AB
Telephone +46 (0)8 695 6930